Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Metagenomi (MGX) EBITDA (2023 - 2025)

Metagenomi (MGX) has disclosed EBITDA for 3 consecutive years, with -$22.6 million as the latest value for Q4 2025.

  • Quarterly EBITDA rose 6.94% to -$22.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$88.3 million through Dec 2025, down 14.32% year-over-year, with the annual reading at -$88.3 million for FY2025, 14.32% down from the prior year.
  • EBITDA for Q4 2025 was -$22.6 million at Metagenomi, down from -$20.4 million in the prior quarter.
  • The five-year high for EBITDA was -$10.7 million in Q2 2024, with the low at -$25.3 million in Q1 2024.
  • Average EBITDA over 3 years is -$19.5 million, with a median of -$20.0 million recorded in 2023.
  • The sharpest move saw EBITDA increased 18.64% in 2024, then plummeted 87.93% in 2025.
  • Over 3 years, EBITDA stood at -$19.0 million in 2023, then fell by 27.83% to -$24.3 million in 2024, then grew by 6.94% to -$22.6 million in 2025.
  • According to Business Quant data, EBITDA over the past three periods came in at -$22.6 million, -$20.4 million, and -$20.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.